Gene · 2122
Papers2,623
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,623
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Expanding the phenotypic spectrum of MECOM-associated syndrome: rare variants are associated with syndromic pulmonary arterial hypertension. | J Med Genet | 2026 | 41617498 | PubTator, text mining | PubMed |
| Low-VAF TP53-Mutated AML Displays Distinct Biological Features in a Single-Center Cohort. | Biomedicines | 2026 | 41595714 | PubTator, text mining | PubMed |
| Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML. | Hemasphere | 2026 | 41551728 | PubTator, text mining | PubMed |
| Artificial Intelligence Virtual Organoids (AIVOs). | Bioact Mater | 2026 | 41536916 | PubTator, text mining | PubMed |
| Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy. | Hemasphere | 2026 | 41531664 | PubTator, text mining | PubMed |
| MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer. | Cancer Res | 2026 | 41529070 | PubTator, text mining | PubMed |
| Optical genome mapping as a high-resolution tool for uncovering cytogenetic complex and cryptic alterations in a cohort of patients with MDS and AML. | NPJ Precis Oncol | 2026 | 41501393 | PubTator, text mining | PubMed |
| Molecular Characterization of <italic>MECOM</italic> Rearrangements in Two Cases with Myelodysplastic Syndrome and t(2;3)(p23;q26.2). | Cytogenet Genome Res | 2026 | 41417673 | PubTator, text mining | PubMed |
| Mechanisms of enhancer-driven oncogene activation. | Int J Cancer | 2026 | 39853740 | PubTator, text mining | PubMed |
| Genocopy of EVI1-AML with paraneoplastic diabetes insipidus: PRDM16 overexpression by t(1;2)(p36;p21) and enhancer hijacking. | Br J Haematol | 2026 | 39587921 | PubTator, text mining | PubMed |
| Low EVI1 expression at diagnosis identifies a high-risk subgroup in adult Ph-negative B-cell acute lymphoblastic leukemia. | Front Med (Lausanne) | 2025 | 41608431 | PubTator, text mining | PubMed |
| Development and validation of a glycosyltransferase-associated prognostic model for melanoma and characterization of the tumor immune microenvironment using single-cell sequencing data. | Biochem Biophys Rep | 2025 | 41542167 | PubTator, text mining | PubMed |
| Thrombopoietin increases susceptibility for EVI1 + KMT2A-MLLT3-driven AML expressing stem cell genes linked to poor outcome. | Nat Commun | 2025 | 41419472 | PubTator, text mining | PubMed |
| Unraveling hematopoietic stem cell ontogeny through single-cell multi-omics approaches. | Front Cell Dev Biol | 2025 | 41358001 | PubTator, text mining | PubMed |
| MECOM amplified endometrial cancer, a novel subset of copy number high tumors associated with poor prognosis. | Gynecol Oncol Rep | 2025 | 41340866 | PubTator, text mining | PubMed |
| Methodological landscape in the field of integration site identification of retroviruses and retroviral vectors. | Front Bioeng Biotechnol | 2025 | 41306907 | PubTator, text mining | PubMed |
| MECOM-Rearranged Acute Myeloid Leukemia: Pathobiology and Management Strategies. | Hematol Rep | 2025 | 41283235 | PubTator, text mining | PubMed |
| Recovering the pre-colonial population structure of Khoe-San descendant populations. | bioRxiv | 2025 | 41279563 | PubTator, text mining | PubMed |
| Prognostic significance of cytogenetic and molecular features in pediatric acute myeloid leukemia: a meta-analysis. | BMC Cancer | 2025 | 41250004 | PubTator, text mining | PubMed |
| Short Inverted Repeats as Mutational Hotspots and Putative Drivers of Genome Instability in Osteosarcoma. | Genes (Basel) | 2025 | 41153425 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2122/papers?page=3